Both miR-185 and 342 inhibited the expression of SREBP-1 and SREBP-2 and their downstream genes, FASN and HMGCR, and further decreased the levels of fatty acid and cholesterol in prostate cancer cells. The gene discussed is SREBF1; the disease is prostate carcinoma.